ONC
Beone Medicines·NASDAQ
--
--(--)
--
--(--)
4.88 / 10
Netural
Fund‑flow rating is good (7.67/10) with medium and large investors net inflowing, though overall trend is negative. Analyst coverage is limited: one Buy, one Neutral, weighted rating 2.08, and price down 2.29%. Sentiment remains mixed, leaning slightly positive on cash flows.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-16
InstitutionJefferies
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for ONC?
- ONC holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.88/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
